PTHS revenueQ2 2026$15.60M
- QoQ
- +43.1%
PTHS revenue was $15.60M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier and up 43.1% from the prior quarter. For the full fiscal 2025 it was $16.80M, compared with $0 in fiscal 2024.
Pelthos Therapeutics Inc. (PTHS) financials
For the twelve months ended Jun 30, 2026, Pelthos Therapeutics Inc. reported $43.30M of revenue and -$86.39M of net income.
- Revenue, TTM
- $43.30M
- Net income, TTM
- -$86.39M
- Net margin
- -199.5%
- Cash
- $24.19M
- P/S
- 0.81
- Market cap
- $35.0M
FY2024FY2025
FY2022FY2025
FY2024FY2025
PTHS revenue and earnings growth
PTHS net incomeQ2 2026-$23.42M
PTHS net income was -$23.42M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.45M a year earlier. For the full fiscal 2025 it was -$43.32M, compared with -$7.96M in fiscal 2024.
PTHS EPSQ2 2026-$6.62
PTHS diluted EPS was -$6.62 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$23.04.
PTHS free cash flowQ2 2026-$7.67M
PTHS free cash flow was -$7.67M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$447.0K a year earlier. For the full fiscal 2025 it was -$22.69M, compared with -$5.79M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $16.80M | $0 | - | - |
| Cost of revenue | $3.99M | $0 | - | - |
| Gross profit | $12.81M | $0 | - | - |
| Research and development | $1.23M | $1.18M | $2.58M | $391.7K |
| Selling, general and admin | $42.45M | $6.39M | $2.74M | $1.10M |
| Operating income | -$32.43M | -$7.57M | -$6.86M | -$2.32M |
| Interest expense | $3.01M | $786.0K | - | - |
| Pre-tax income | -$50.71M | -$7.96M | -$7.38M | -$2.46M |
| Income tax | -$7.39M | $0 | - | - |
| Net income | -$43.32M | -$7.96M | -$7.38M | -$2.46M |
| EPS, basic | -$23.04 | -$14.27 | -$5.78 | $5.65 |
| EPS, diluted | -$23.04 | -$14.27 | -$5.78 | - |
| Diluted shares | 1.9M | 557,447 | 1.3M | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $17.97M | $513.0K | $96.0K | $55.1K |
| Receivables | $8.86M | $0 | - | - |
| Inventory | $23.57M | $0 | - | - |
| Current assets | $53.41M | $1.37M | $96.4K | $55.1K |
| Goodwill | $24.68M | $0 | - | - |
| Total assets | $130.40M | $1.37M | $96.4K | $55.1K |
| Current liabilities | $25.99M | $4.08M | $6.54M | $3.76M |
| Total liabilities | $91.52M | $4.08M | $6.54M | $3.76M |
| Shareholders' equity | $38.88M | -$2.71M | -$6.45M | -$3.71M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$22.59M | -$5.79M | -$981.0K | -$1.57M |
| Capital expenditures | $99.0K | $0 | - | - |
| Free cash flow | -$22.69M | -$5.79M | - | - |
| Investing cash flow | -$5.24M | $0 | - | - |
| Financing cash flow | $45.34M | $6.21M | $1.02M | $1.62M |
| Share repurchases | $0 | $75.0K | - | - |
| Stock-based compensation | $5.46M | $1.80M | $1.73M | $110.1K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.60M | $10.91M | $9.39M | $7.41M | $0 | $0 | - | - | - | - | - | - |
| Cost of revenue | $3.61M | $1.67M | $1.67M | $2.32M | $0 | $0 | - | - | - | - | - | - |
| Gross profit | $11.99M | $9.23M | $7.72M | $5.09M | $0 | $0 | - | - | - | - | - | - |
| Research and development | $600.0K | $186.0K | $374.0K | $145.0K | $515.0K | $194.0K | $285.0K | $415.0K | $13.0K | $466.6K | $2.29M | $49.1K |
| Selling, general and admin | $27.67M | $21.10M | $18.47M | $19.63M | $2.72M | $1.64M | $1.54M | $1.63M | $1.21M | $787.6K | $1.06M | $661.6K |
| Operating income | -$17.32M | -$13.09M | -$12.00M | -$15.36M | -$3.23M | -$1.83M | -$1.82M | -$2.05M | -$1.76M | -$1.93M | -$3.88M | -$1.29M |
| Interest expense | $2.39M | $2.35M | $1.31M | $1.35M | $218.0K | $134.0K | $108.0K | $39.0K | $639.0K | $0 | - | - |
| Pre-tax income | -$23.42M | -$25.07M | -$28.59M | -$16.70M | -$3.45M | -$1.97M | -$1.93M | -$1.70M | -$1.77M | -$2.56M | -$4.04M | -$1.42M |
| Income tax | $0 | $0 | -$6.92M | -$465.0K | $0 | $0 | - | - | - | - | - | - |
| Net income | -$23.42M | -$25.07M | -$21.66M | -$16.24M | -$3.45M | -$1.97M | -$1.93M | -$1.70M | -$1.77M | -$2.56M | -$4.04M | -$1.42M |
| EPS, basic | -$6.62 | -$7.57 | - | -$5.30 | -$5.29 | -$3.21 | - | -$2.93 | -$3.07 | -$0.55 | - | -$1.44 |
| EPS, diluted | -$6.62 | -$7.57 | - | -$5.30 | -$5.29 | -$3.21 | - | -$2.93 | -$3.07 | -$0.55 | - | - |
| Diluted shares | 3.5M | 3.3M | - | 3.1M | 651,921 | 612,889 | - | 579,229 | 577,371 | 4.7M | - | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $24.19M | $31.98M | $17.97M | $14.20M | $59.0K | $131.0K | $513.0K | $1.25M | $2.41M | $3.77M | $96.0K | $22.8K |
| Receivables | $14.48M | $11.70M | $8.86M | - | - | - | $0 | - | - | - | - | - |
| Inventory | $21.47M | $23.42M | $23.57M | $24.10M | - | - | $0 | - | - | - | - | - |
| Current assets | $63.36M | $69.80M | $53.41M | $49.76M | $822.9K | $911.2K | $1.37M | $2.14M | $2.60M | $4.03M | $96.4K | - |
| Goodwill | $24.68M | $24.68M | $24.68M | $30.63M | - | - | $0 | - | - | - | - | - |
| Total assets | $137.36M | $145.38M | $130.40M | $126.43M | $822.9K | $911.2K | $1.37M | $2.14M | $2.60M | $4.03M | $96.4K | - |
| Current liabilities | $31.96M | $25.00M | $25.99M | $24.77M | $7.32M | $5.11M | $4.08M | $3.57M | $2.79M | $2.90M | $6.54M | - |
| Total liabilities | $138.86M | $126.11M | $91.52M | $68.18M | $7.32M | $5.11M | $4.08M | $3.57M | $2.79M | $2.90M | $6.54M | - |
| Shareholders' equity | -$1.50M | $19.27M | $38.88M | $58.25M | -$6.50M | -$4.20M | -$2.71M | -$1.43M | -$184.0K | $1.13M | -$6.45M | -$5.90M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.66M | -$13.13M | -$6.25M | -$15.26M | -$447.0K | -$632.0K | -$670.0K | -$177.7K | -$2.95M | -$1.99M | -$356.8K | -$257.2K |
| Capital expenditures | $2.0K | $194.0K | - | - | $0 | $0 | - | - | - | - | - | - |
| Free cash flow | -$7.67M | -$13.32M | - | - | -$447.0K | -$632.0K | - | - | - | - | - | - |
| Investing cash flow | -$2.0K | -$194.0K | -$8.00M | $2.76M | $0 | $0 | - | - | - | - | - | - |
| Financing cash flow | $0 | $27.52M | $18.02M | $26.69M | $375.0K | $250.0K | -$72.0K | -$972.0K | $1.59M | $5.67M | $430.4K | $198.1K |
| Stock-based compensation | $2.76M | $1.91M | $1.80M | $2.76M | $413.0K | $486.0K | $530.0K | $517.5K | $459.0K | $292.6K | $791.2K | $342.4K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 76.9% | 84.7% | 82.2% | 68.7% | - | - | - | - | - | - | - | - |
| Operating margin | -111.0% | -120.0% | -127.8% | -207.4% | - | - | - | - | - | - | - | - |
| Net margin | -150.1% | -229.9% | -230.7% | -219.3% | - | - | - | - | - | - | - | - |
| Free cash flow margin | -49.1% | -122.1% | - | - | - | - | - | - | - | - | - | - |
| Current ratio | 1.98 | 2.79 | 2.05 | 2.01 | 0.11 | 0.18 | 0.34 | 0.60 | 0.93 | 1.39 | 0.01 | - |
Source: XBRL data Pelthos Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PTHS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PTHS | $43.30M | - | -$86.39M | -199.5% | $35.0M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $211.94B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.49B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $60.30B |
| RVMD | $0 | - | -$1.13B | - | $41.76B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.44B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.91B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.22B |
PTHS FAQ
6 questionsWhat is PTHS revenue?
Pelthos Therapeutics Inc. (PTHS) reported $43.30M of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $16.80M.Is PTHS profitable?
No. Pelthos Therapeutics Inc. reported a net loss of $86.39M for the twelve months ended Jun 30, 2026.How much cash and debt does PTHS have?
Pelthos Therapeutics Inc. reported $24.19M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PTHS gross margin?
Pelthos Therapeutics Inc.'s gross profit was $34.03M on $43.30M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 78.6%.When did PTHS last report financial results?
The latest statements here come from Pelthos Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this PTHS financial data come from?
Quantisnow builds these statements from the structured XBRL data Pelthos Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.